CervoMed Reports Positive Phase 2b Trial Results

CervoMed ( (CRVO) ) has provided an update.

On April 2, 2025, CervoMed announced positive clinical results from the first sixteen weeks of the open-label extension phase of their RewinD-LB Phase 2b clinical trial for neflamapimod, a treatment for dementia with Lewy bodies. The trial showed that neflamapimod slowed clinical progression and reduced falls compared to controls, with improvements in cognitive fluctuations and working memory. These findings, presented at the AD/PD 2025 conference, support the potential of neflamapimod as a transformative therapy for patients with dementia with Lewy bodies, and CervoMed plans to engage with regulatory authorities to finalize Phase 3 plans.

Spark’s Take on CRVO Stock

According to Spark, TipRanks’ AI Analyst, CRVO is a Neutral.

CervoMed’s stock score is primarily impacted by its financial challenges, with no revenue and persistent losses. However, technical indicators suggest positive momentum, and recent positive clinical trial results may improve future prospects. Valuation poses challenges due to negative earnings, but the potential for clinical success offers a speculative upside.

To see Spark’s full report on CRVO stock, click here.

More about CervoMed

CervoMed is a clinical-stage company focused on developing treatments for age-related neurologic disorders.

YTD Price Performance: 396.86%

Average Trading Volume: 4,776,815

Technical Sentiment Signal: Hold

Current Market Cap: $96.43M

See more insights into CRVO stock on TipRanks’ Stock Analysis page.